Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model

Keizo Takenaga; Miho Akimoto; Nobuko Koshikawa; Hiroki Nagase

doi:10.1371/journal.pone.0232230

. 2020 Apr 27;15(4):e0232230. doi: 10.1371/journal.pone.0232230

Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model

Keizo Takenaga ^1,^*, Miho Akimoto ², Nobuko Koshikawa ¹, Hiroki Nagase ¹

Editor: Sulagna Banerjee³

PMCID: PMC7185704 PMID: 32340025

Abstract

Background

Proinflammatory interleukin-33 (IL-33) binds to its receptor ST2L and is involved in inflammation and the malignant behavior of cancer cells. However, the role of IL-33-ST2L and the IL-33 decoy receptor sST2 in the tumor microenvironment of pancreatic cancer is unclear. Because we previously reported that sST2 derived from colon cancer cells profoundly influences malignant tumor growth, we hypothesized that sST2 released from pancreatic cancer cells also modulates IL-33-ST2L signaling in the tumor microenvironment, thereby influencing tumor growth.

Methods

ST2 (ST2L and sST2) expression in mouse pancreatic cancer Panc02 cells was downregulated by shRNAs. mRNA expression levels of IL-33, ST2, cytokines and chemokines in the cells and tumor tissues were examined using real-time PCR. sST2 secretion and the amount of CXCL3 in tumor tissues were measured using ELISA. Tumor growth was investigated after injection of the cells into the pancreas of C57BL/6 mice. MPO⁺, F4/80⁺ and CD20⁺ cells in tumor tissues were detected using immunohistochemistry.

Results

Some but not all human and mouse pancreatic cancer cell lines preferentially expressed sST2. Then, we investigated the role of sST2 in orthotopic tumor growth of sST2-expressing mouse pancreatic cancer Panc02 cells in immunocompetent mice. shRNA-mediated knockdown of sST2 expression in the cells suppressed orthotopic tumor growth, which was partially recovered by overexpression of shRNA-resistant sST2 mRNA but was not evident in IL-33 knockout mice. This was associated with decreases in Cxcl3 expression, vessel density and accumulation of cancer-associated neutrophils but not cancer-associated macrophages. Administration of SB225002, an inhibitor of the CXCL3 receptor CXCR2, induced similar effects.

Conclusions

Cancer cell-derived sST2 enhances tumor growth through upregulation of CXCL3 via inhibition of IL-33-ST2L signaling in the tumor microenvironment of pancreatic cancer. These results suggest that the sST2 and the CXCL3-CXCR2 axis could be therapeutic targets.

Introduction

Pancreatic cancer is a disease with a poor prognosis. Most patients already have locally advanced or metastatic disease at the time of diagnosis [1, 2]. Furthermore, pancreatic cancer is very hypoxic and often resistant to radiochemotherapy [3–5]. Therefore, a better understanding of the pathophysiological characteristics of pancreatic cancer is critical for the development of more effective therapeutic approaches for patients with pancreatic cancer.

ST2 is encoded by the IL1RL1 gene, is a member of the interleukin-1 (IL-1) receptor family [6] and consists of at least two isoforms, ST2L and sST2, which are produced via alternative splicing [7–9]. ST2L is a transmembrane form and is expressed in a variety of cell types, including Th2 lymphocytes, macrophages and NK cells [7–9], whereas sST2 is a soluble form that is predominantly expressed in fibroblasts, epithelial cells and cancer cells [10, 11].

IL-33 has been shown to be primarily expressed as a proinflammatory cytokine by a variety of cell types, such as epithelial cells, myofibroblasts, fibroblasts and macrophages, either constitutively or in response to different stimuli, including chemokines and cytokines [12–14]. IL-33 binds to the cell surface receptor consisting of ST2L and IL-1 receptor accessory protein (IL-1RAP) [15, 16], which is blocked by the decoy receptor sST2 [10, 11].

Recently, the IL-33/ST2L axis has been shown to be involved in the progression of cancer, either positively or negatively, depending on the cancer type, through modulating the tumor microenvironment, such as infiltration of T cells and inflammation. For example, the amount of serum IL-33 is positively correlated with a poor prognosis in gastric cancer [17], non-small cell lung cancer [18], and hepatocellular carcinoma [19]. IL-33 promotes tumor progression in mouse breast, lung and colon cancers [20, 21] and human colon cancer [22]. Conversely, IL-33 suppresses tumor growth and metastasis in mouse melanoma, lung carcinoma and mammary carcinoma [23, 24]. Thus, the effect of IL-33 on tumor progression might be cell type- and context-dependent. With regard to pancreatic cancer, the role of IL-33 largely remains unexplored. On the one hand, IL-33 is implicated as a crucial mediator in inflammation-associated pancreatic carcinogenesis [25], but on the other hand, it induces apoptosis in human MIAPaCa-2 cells [26]. Thus, the role of the IL-33/ST2L axis in regulating pancreatic cancer progression is unresolved.

We previously demonstrated that colon cancer cell-derived sST2 suppresses tumor growth by inhibiting the Th2 response, M2 macrophage polarization and tumor angiogenesis triggered by IL-33 in the tumor microenvironment [22]. To investigate whether sST2 also suppresses tumor growth in pancreatic cancer, we first examined the expression of sST2 in human and mouse pancreatic cancer cell lines. By employing sST2-expressing pancreatic cancer Panc02 cells in an orthotopic implantation mouse model, we report here that, contrary to expectations, sST2 enhanced orthotopic tumor growth in immunocompetent but not IL-33 knockout mice, which suggests that IL-33-ST2L signaling inhibits pancreatic cancer growth.

Materials and methods

Reagents

Murine recombinant IL-33 (rIL-33) was purchased from R&D Systems, Inc. (McKinley Place NE, MN, USA). SB225002 was obtained from Selleck Chemicals (Tokyo, Japan).

Cells and cell culture

Mouse pancreatic cancer Panc02 cells and the human pancreatic cell lines AsPC-1, BxPC3, CFPAC-1, MIAPaCa-2, Panc-1 and SW1990 were used [27]. Panc02 cells were kindly provided by Dr. T. Hollingsworth of the University of Nebraska Medical Center and were characterized elsewhere [27, 28]. Panc-1 and MIAPaCa-2 cells were obtained from the RIKEN BRC Cell Bank (Tsukuba, Japan), and the other human pancreatic cell lines were purchased from ATCC (Manassas, VA, USA). The cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 40 μg/ml gentamicin in a humidified atmosphere with 95% air/5% CO₂ at 37°C. All cell lines were free of mycoplasma contamination as evaluated using the e-Myco Mycoplasma PCR Detection Kit (Cosmo Bio Co Ltd., Tokyo, Japan).

ST2 knockdown by shRNAs

For ST2 knockdown in Panc02 cells, MISSION mouse ST2 shRNA lentiviral vectors (#3: TRCN0000058517 for knockdown of both ST2L and sST2 and #5; TRCN0000039054 for knockdown of only sST2) in the pLKO.1-puro plasmid (Sigma-Aldrich Japan, Tokyo, Japan) were used [22]. Lentiviral stocks encoding the shRNA were prepared as previously described [22]. Panc02 cells were transduced with MISSION pLKO.1-puro control transduction particles or shRNA lentiviruses and selected with puromycin (5 μg/ml) to establish control cells (shCont cells) or cells that displayed stable downregulation of both ST2L and sST2 (sh#3 cells) or only sST2 (sh#5 cells), respectively.

Forced sST2 expression in shsST2 knockdown Panc02 cells

To recover sST2 expression in Panc02-sh#5 cells, the cells were transfected with the plasmid pcDNA3.1/sST2Δ3’-UTR, which lacks the target sequence of #5 ST2 shRNA, using Lipofectamine 2000 according to the manufacturer’s protocol. The cells were then selected with 400 μg/ml G418 to establish Panc02-sh#5-sST2 cells. For the control, Panc02-sh#5 cells were transfected with pcDNA3.1 to establish Panc02-sh#5-VC with the same procedure.

MTT assay

Cell growth and viability were measured by using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Briefly, cells (2×10⁴ cells/well) were cultured in 96-well tissue culture plates and treated in triplicate with different concentrations of rIL-33 or solvent alone for 2 days. At the end of the incubation, 10 μl of MTT (2.5 mg/ml) (Sigma-Aldrich) was added to the wells for 4 h to allow the formation of MTT formazan crystals. After the medium was removed, the crystals were solubilized in 100 μl of DMSO. The absorbance was recorded at 550 nm.

RNA preparation and qRT-PCR

One microgram of total RNA was extracted from cells or tumor tissues and reverse-transcribed with a ReverTra Ace qPCR RT kit (TOYOBO, Osaka, Japan). qRT-PCR was performed on cDNA using THUNDERBIRD SYBR qPCR Mix (TOYOBO) and 0.3 μM primers, as shown in S1 Table. The PCR protocol consisted of an initial denaturation step at 95°C for 1 min and 40 cycles of denaturation (95°C for 15 s) and extension (60°C for 1 min). The mRNA expression level of each gene in the cells or tumors was normalized to Gapdh.

Quantification of sST2 and IL-33 by ELISA

Conditioned media were harvested after 24 h of culture and centrifuged at 15,000 × g for 20 min at 4°C. For serum preparation, blood was allowed to clot and centrifuged for 10 min at 1,000 g. sST2 and IL-33 concentrations were measured with the Mouse ST2/IL-1 R4 Quantikine ELISA Kit (R&D Systems) and the Mouse/Rat IL-33 Quantikine ELISA Kit (R&D Systems), respectively, according to the manufacturer’s instructions.

Profiling chemokine and cytokine gene expression

Chemokine and cytokine genes that were differentially expressed in Panc02-shCont versus Panc02-sh#5 cells were profiled by a Mouse Cytokines & Chemokines RT² Profiler PCR Array (QIAGEN, Hilden, Germany).

Tumor transplantation

All animal handling and experimental procedures were performed in compliance with the institutional guidelines for the care and use of animals in research. The protocol was approved by the Committee on the Ethics of Animal Experiments of Chiba Cancer Center (Permission Number: 18–1) and the IZUMO Campus Animal Care and Use Committee of Shimane University (Permission Number: IZ26-7). Six- to 7-week-old male C57BL/6J and C57BL/6N mice (20~25 g body weight, CLEA Japan, Osaka, Japan) were used in this study. C57BL/6N-IL-33^-/- mice (CDB0631K) [29] were obtained from RIKEN CDB (Kobe, Japan) (http://www.cdb.riken.jp/arg/mutant%20mice%20list.html). The mice were bred in-house and weaned at 21 days of age, and approximately 7 weeks later, they were subjected to orthotopic tumor implantation. A total of 120 mice were used in this study. All mice were housed in a barrier facility under specific pathogen-free conditions at a controlled temperature of 23±2°C with 55±10% humidity and 12 h light/12 h dark light cycles. The animals were maintained on a sterilized standard diet and water. Panc02 variant cells (2×10⁵ cells) were orthotopically implanted into mice (4~7 mice per group). For this, the cells were implanted with 50% low-temperature Matrigel into the parenchyma of pancreatic tails of anesthetized mice with medetomidine (0.3 mg/kg)/midazolam (4.0 mg/kg)/butorphanol (5.0 mg/kg). The pancreas and spleen were exteriorized through a laparotomy, and the cells were injected using a 30-gauge needle attached to an insulin syringe. The mice and surgical wounds were observed and evaluated at least once a day for a minimum of one week until the mice returned to normal behavior and physical condition. Thereafter, the mice were examined daily for their health, including infection, wound dehiscence and excessive weight loss, and, if necessary, the mice received subcutaneous administration of analgesics to minimize pain and distress. At the end of a study, the mice were euthanized by continued CO₂ inhalation for at least 15 min after respiratory arrest following an IACUC approved protocol in which humane study endpoint criteria were described. In this study, the mice were euthanized before obvious distress, failure to ambulate, or weight loss > 10% was evident. Tumors were excised and weighed. Tumor volume (V) was calculated using the following equation: V = (a² x b)/2, where a is the small diameter and b the large diameter.

SB225002 administration

To investigate the effect of SB225002 on tumor growth, C57BL/6J mice were orthotopically implanted with Panc02-shCont cells (2×10⁵ cells in 50% Matrigel). Three days after injection, the mice were randomly (simple randomization) and blindly grouped into the vehicle (n = 11 mice) and SB225002 groups (n = 12 mice). In the SB225002 group, the mice were intraperitoneally administered 2 mg/kg SB225002 dissolved in 1% DMSO/10% PEG300/0.33% Tween 80/DPBS with single daily dosing. In the vehicle group, the mice were administered vehicle alone. Tumors were resected and weighed on Day 21 after Panc02 implantation.

Immunohistochemical analysis of CD31 using frozen sections

Surgically removed Panc02 tumors were embedded and frozen in OCT compound. Cryostat sections (8-μm thick) were fixed in 4% paraformaldehyde for 10 min and blocked with 1% BSA in DPBS. The sections were incubated with rat anti-mouse monoclonal CD31 antibody (1:100 dilution) (BD Biosciences, Franklin Lake, NJ, USA) followed by incubation with Alexa Fluor 594-conjugated goat anti-rat IgG (1:300 dilution) (Thermo Fisher Scientific) and counterstaining with DAPI. Images were taken with a confocal laser scanning microscope (TCS SC8, Leica Microsystems, Wetzlar, Germany), and pixel values of the CD31-positive areas were calculated for each image to determine the tumor vessel density using ImageJ software (National Institutes of Health).

Immunohistochemical analysis of paraffin-embedded tissues

Tumors were surgically removed and fixed in 10% phosphate-buffered formalin solution. The tissues were embedded in paraffin and cut into 2-μm sections. After heat-induced antigen retrieval in REAL Target Retrieval Solution (DAKO) and subsequent blocking of nonspecific sites with 0.1% normal goat serum/1% BSA, the tissues were immunostained with rabbit polyclonal anti-myeloperoxidase (MPO) antibody (Bioss Inc., Boston, MA, USA) diluted 1:200 using a previously described method [22]. The tissues were also immunostained with rabbit polyclonal anti-MPO antibody or rabbit polyclonal anti-CD20 antibody (Thermo Fisher Scientific) diluted 1:200, followed by Alexa Fluor 594-conjugated goat anti-rat IgG or phycoerythrin (PE)-conjugated rat monoclonal anti-mouse F4/80 (Abcam) diluted 1:100. In some experiments, after the tissues were treated with M.O.M. (Mouse on Mouse) Immunodetection Kit-Fluorescein (Vector Laboratories, Inc., Burlingame, CA, USA), the tissues were double immunostained with 10 μg/ml goat anti-mouse IL-33 IgG (R&D Systems, Minneapolis, MN, USA) and mouse monoclonal anti-α-SMA antibody diluted 1:100 (DAKO), followed by Alexa Fluor 594-conjugated chicken anti-goat IgG and Alexa Fluor 488-conjugated goat anti-mouse IgG. The sections were treated with the Vector TrueVIEW Autofluorescence Quenching Kit (Vector Laboratories) and counterstained with DAPI.

Quantification of CXCL3 in tumor tissues by ELISA

Tumor tissue lysates were prepared as previously described [22]. Mouse CXCL3 concentrations were measured with the Cxcl3 ELISA Kit (Mouse) (Aviva Systems Biology, Corp. San Diego, CA, USA) according to the manufacturer's instructions.

Statistical analysis

All data are presented as the mean ± SD. Statistical significance was tested using one-way ANOVA accompanied by pairwise comparisons with a t-test. Statistical significance in tumor weights between two groups was tested by the Mann-Whitney U test. A value of P<0.05 was considered significant.

Results

Association between IL33 and ST2 expression and prognosis in pancreatic cancer patient databases

To examine the association between IL33 and ST2 (IL1RL1) expression and prognosis in pancreatic cancer patients, we searched the public prognosis databases PROGgeneV2 (http://watson.compbio.iupui.edu/chirayu/proggene/database/?url=proggene) and SurvExpress (http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp). The datasets showed a trend toward poorer overall survival (OS) in patients with low expression of IL33 than in patients with high expression in two out of three datasets (S1 Fig). On the other hand, the association between ST2 expression and overall survival was inconsistent; patients with low ST2 expression showed poorer OS than those with high expression in one dataset (GSE57495), whereas in other datasets, the association was the complete opposite (GSE71729) or less relevant (PAAD-TCGA) (S1 Fig). Thus, we could not find a consistent association between IL-33 and ST2 expression and prognosis. However, because IL-33-ST2L signaling is modulated by the amount of sST2 and microarray analyses measure only ST2L or do not draw a distinction between ST2L and sST2, we thought that evaluating the effect of sST2 released from cancer cells during tumor growth is important for proper prognostic analyses. This prompted us to embark on a study to reveal the role of sST2 in the tumor microenvironment of pancreatic cancer.

First, we measured the expression of sST2 in six human pancreatic cancer cell lines and found that two cell lines (BxPC3 and CFPAC-1) expressed a large amount of sST2 mRNA, while the other cell lines expressed little sST2 mRNA. The expression of ST2L mRNA was quite low in all cell lines (Fig 1A, S2 Fig). These results suggest that the amount of sST2 in pancreatic cancer tissues may be considerably different in every patient, which might bias the analyses of the association between IL-33 and ST2L expression and prognosis.

Fig 1 — qRT-PCR analysis of the expression of *ST2L* and *sST2*. The expression level was normalized to that of *GAPDH*. (A) Human pancreatic cancer cell lines. (B) Mouse pancreatic cancer Panc02 cells.

Downregulation of sST2 expression in Panc02 cells inhibits orthotopic tumor growth

We assumed that the change in the expression level of sST2 in pancreatic cancer cells might affect tumor growth by influencing IL-33-ST2L signaling in the tumor microenvironment. To test this possibility, we employed an orthotopic implantation model in immunocompetent mice using Panc02 cells that express sST2 (Fig 1B). Panc02 cells expressed very little IL-33 mRNA, and Panc02 variant cells (see below) did not secrete IL-33 protein (S3 Fig). Because IL-33 is reported to induce apoptosis in human pancreatic cancer MIAPaCa-2 cells [26], we first checked the effect of IL-33 on the growth of Panc02 cells and confirmed that IL-33 did not induce cell death in these cells (S4 Fig). We then knocked down ST2 expression by shRNA (sh#3 for knockdown of both ST2L and sST2 and sh#5 for knockdown of sST2 only). As a result, we established Panc02-sh#3 cells and Panc02-sh#5 cells that showed a reduced level of sST2 compared to that of Panc02-shCont cells at both the mRNA and the protein levels (Fig 2A and 2B). The in vitro growth of both Panc02-sh#3 and Panc02-sh#5 cells was comparable to that of Panc02-shCont cells (Fig 2C). However, when these cells were injected into the pancreas of C57BL/6J mice, both Panc02-sh#3 and Panc02-sh#5 cells formed significantly smaller tumors than Panc02-shCont cells (Fig 2D–2F).

Fig 2 — (A) Knockdown of sST2 expression by ST2 shRNA. The expression levels of sST2 in Panc02-shCont, Panc02-sh#3 and Panc02-sh#5 cells were normalized to the expression of *Gapdh* and are presented as the ratio to the expression in Panc02-shCont cells (n = 3). (B) Secretion of sST2 by Panc02-shCont (n = 3), Panc02-sh#3 (n = 3) or Panc02-sh#5 cells (n = 3). (C) *In vitro* growth of Panc02-shCont, Panc02-sh#3 or Panc02-sh#5 cells (n = 3). (D) Orthotopic tumor growth of Panc02-shCont, Panc02-sh#3 and Panc02-sh#5 cells. The cells were implanted into the pancreas of C57BL/6J mice. Three weeks later, the pancreas and spleen (upper) were removed, and the tumors were excised (lower). (E) Orthotopic tumor volume formed by Panc02-shCont (n = 5 mice), Panc02-sh#3 (n = 6 mice) and Panc02-sh#5 cells (n = 7 mice). (F) Orthotopic tumor weight. Similar results were obtained in three independent experiments. The data are shown as the mean ± SD. *P<0.05. **P<0.001.

Because sST2 was commonly suppressed in Panc02-sh#3 and Panc02-sh#5 cells, the suppression of tumor growth seemed to be due to sST2 depletion. To confirm this, we first measured sST2 and IL-33 in the sera of tumor-bearing mice. The results showed that the amount of serum sST2 was much less in the mice bearing Panc02-sh#3 and Panc02-sh#5 tumors than in the mice bearing Panc02-shCont tumors, whereas the IL-33 level was comparable among them (S5 Fig). Next, we transfected the expression vector harboring sST2 cDNA that lacks the #5 ST2 shRNA target sequence (pcDNA3.1/sST2Δ3’UTR) into Panc02-sh#5 cells. The resulting cells, Panc02-sh#5-sST2, expressed more sST2 at both the mRNA and the protein levels than Panc02-sh#5-VC cells that had been transfected with the vector alone (Fig 3A and 3B). Panc02-sh#5-sST2 cells grew slightly slower than Panc02-sh#5-VC and Panc02-shCont cells in vitro (Fig 3C). As expected, when the cells were injected into the pancreas of C57BL/6J mice, Panc02-sh#5-sST2 cells developed larger tumors than Panc02-sh#5-VC cells (Fig 3D–3F). However, Panc02-sh#5-sST2 tumors were smaller than Panc02-shCont tumors; the reason for this was unknown but could be due to insufficient recovery of sST2 or undesired effects of plasmid introduction and G418 selection. We also injected Panc02-shCont and Panc02-sh#5 cells into the pancreas of C57BL/6N and C57BL/6N-IL-33^-/- (IL-33 KO) mice. Again, Panc02-sh#5 cells formed smaller tumors than Panc02-shCont cells in C57BL/6N mice. However, they formed tumors of equivalent size in IL-33 KO mice (Fig 3G–3I), indicating the involvement of IL-33 signaling in the difference in orthotopic tumor growth between Panc02-shCont and Panc02-sh#5 cells in wild-type mice. Thus, these results indicate that sST2 enhances orthotopic tumor growth of Panc02 cells by inhibiting the IL-33 response in the tumor microenvironment.

Fig 3 — (A) Establishment of Panc02-sh#5 cells that re-express sST2. RT-qPCR analysis of *sST2* in Panc02-shCont (n = 3), Panc02-sh#5-VC (n = 3) and Panc02-sh#5-sST2 cells (n = 3). The expression levels are normalized to the expression of *Gapdh* and are presented as the ratio to the expression in Panc02-shCont cells. (B) Secretion of sST2 by Panc02-shCont (n = 3), Panc02-sh#5-VC (n = 3) or Panc02-sh#5-sST2 cells (n = 3). (C) *In vitro* growth of Panc02-shCont (n = 3), Panc02-sh#5-VC (n = 3) or Panc02-sh#5-sST2 cells (n = 3). (D) Orthotopic tumor growth of Panc02-shCont, Panc02-sh#5-VC and Panc02-sh#5-sST2 cells. The cells were implanted into the pancreas of C57BL/6J mice. Three weeks later, the pancreas and spleen (upper) were removed, and the tumors were excised (lower). Bar: 1 cm. (E) Orthotopic tumor volume formed by Panc02-shCont (n = 5 mice), Panc02-sh#5-VC (n = 7 mice) and Panc02-sh#5-sST2 cells (n = 6 mice). (F) Orthotopic tumor weight. (G) Orthotopic tumor growth of Panc02-shCont and Panc02-sh#5 cells in C57BL/6N and C57BL/6N-IL-33^-/- mice. The cells were implanted into the pancreas of C57BL/6N (n = 5 mice for Panc02-shCont cells, n = 5 mice for Panc02-sh#5 cells) or C57BL/6N-IL-33-/- mice (n = 4 mice for Panc02-shCont cells, n = 6 mice for Panc02-sh#5 cells). Bar: 1 cm. (H) Orthotopic tumor volume formed by Panc02-shCont cells and Panc02-sh#5 cells in C57BL/6N (n = 5 mice for Panc02-shCont cells, n = 5 mice for Panc02-sh#5 cells) or C57BL/6N-IL-33-/- (IL-33 KO) mice (n = 4 mice for Panc02-shCont cells, n = 6 mice for Panc02-sh#5 cells). (I) Orthotopic tumor weight. *P<0.05, **P<0.001. ns, not significant.

Gene expression of cytokines and chemokines in orthotopic tumors

We compared the levels of IL-33 and ST2L mRNA in Panc02-sh#5 tumors to those in Panc02-shCont tumors and found that they were nearly equal (Fig 4A). Immunohistochemical staining revealed that IL-33 protein as mostly localized in the cytoplasm of α-SMA-positive cells, which were probably pancreatic stellate cells or cancer-associated fibroblasts in the tumor microenvironment (S6 Fig), suggesting that these cells are the major source of secretory IL-33 protein. Then, to determine possible mechanisms underlying the difference in orthotopic tumor growth between Panc02-shCont and Panc02-sh#5 cells, we compared the cytokine and chemokine gene expression profiles between the Panc02-shCont and Panc02-sh#5 tumors using a PCR array platform. The results showed that the expression of Cxcl3, which encodes a neutrophil chemoattractant, was significantly downregulated in Panc02-sh#5 tumors (Fig 4B). By using RT-qPCR analysis, we found that among the members of the CXC chemokine family, Cxcl2, Cxcl3 and Cxcl5 showed relatively abundant expression in orthotopic tumors, but only Cxcl3 was significantly downregulated in Panc02-sh#5 tumors (Fig 4C). There was no difference in the expression of Cxcr2, the receptor for these chemokines (Fig 4C). Because these chemokines had very little expression in Panc02 cells (Fig 4C), they seemed to derive from stromal cells in the tumor microenvironment. It may be worthwhile to note that Oncomine datasets showed that Cxcl3 expression was relatively high in human pancreatic adenocarcinomas (https://www.oncomine.org/resource/login.html) (S7 Fig). On the other hand, Cxcl13, which encodes a B cell chemoattractant [30], was the most upregulated gene in Panc02-sh#5 tumors in the PCR array analysis (Fig 4B). However, this was not statistically significant in the RT-qPCR analysis because the expression level varied considerably among tumor samples (Fig 4D).

To examine whether IL-33 influences the expression of sST2 and ST2L in Panc02 cells, we treated the cells with various concentrations of rIL-33 for up to 24 h. As a result, we found that rIL-33 slightly but significantly increased the mRNA expression of both sST2 and ST2L (S8 Fig). These results suggest that IL-33 in the tumor microenvironment enhances the secretion of sST2 from tumor cells, which in turn enhances orthotopic tumor growth. We further examined the effect of rIL-33 on the expression of Cxcl3 in Panc02 cells. However, the basal expression level of Cxcl3 in the cells was very low, although rIL-33 only slightly increased Cxcl3 expression (S9 Fig).

CXCL3-mediated infiltration of neutrophils and microvessel density in orthotopic tumors

ELISA analysis also confirmed the lower expression of CXCL3 in Panc02-sh#5 tumors than in Panc02-shCont tumors (Fig 5A). CXCL3 is known to recruit and activate neutrophils and enhance angiogenesis by binding to its receptor, CXCR2, which is expressed mainly on neutrophils and endothelial cells [31–33]. Then, we compared neutrophil infiltration and microvessel density between Panc02-shCont and Panc02-sh#5 orthotopic tumors. Immunostaining of the neutrophil marker MPO showed few MPO⁺ cells in Panc02-sh#5 tumors compared to those in Panc02-shCont tumors (Fig 5B and 5C). RT-qPCR analysis showed that the expression of another neutrophil marker gene, Ly6G, was also lower in Panc02-sh#5 cells than in Panc02-shCont cells (Fig 5D). However, the tumor infiltration of F4/80⁺ macrophages and CD20⁺ B cells was not significantly different between the Panc02-shCont and Panc02-sh#5 tumors (Fig 5B, 5E and 5F). CD31 immunostaining revealed a significantly lower vessel density in Panc02-sh#5 tumors than in Panc02-shCont tumors (Fig 5G and 5H).

Inhibition of CXCR2 signaling suppresses orthotopic tumor growth

To confirm whether CXCR2 signaling is involved in Panc02 orthotopic tumor growth, we examined the effect of the CXCR2 antagonist SB225002. For this purpose, SB225002 was administered intraperitoneally every day at a dose of 2 mg/kg for 16 days to mice bearing Panc02-shCont orthotopic tumors (Fig 6A). The results showed that SB225002 suppressed orthotopic tumor growth without body weight loss (Fig 6B–6E). Furthermore, both neutrophil infiltration (Fig 6F and 6G) and vessel density (Fig 6H and 6I) in SB225002-treated tumors were significantly lower than those in control tumors. Thus, these results suggest that the CXCL3/CXCR2 axis is at least responsible for neutrophil infiltration, tumor angiogenesis and slowed orthotopic tumor growth and may be involved in the difference in orthotopic tumor growth between Panc02-shCont and Panc02-sh#5 cells.

Fig 6 — (A) Protocol used for SB225002 administration. Panc02 cells (2 × 10⁵ cells in 50% Matrigel) were inoculated into the pancreas. Three days after inoculation, SB225002 (2 mg/kg) (n = 12 mice per group) or vehicle alone (n = 11 mice per group) was administered intraperitoneally every day for 16 days. The mice were euthanized, and the tumors were removed on Day 18. (B) Body weight. (C) Orthotopic tumors. Bar: 1 cm. (D) Tumor volume. (E) Tumor weight. (F) IHC analysis of MPO⁺ neutrophil infiltration in Panc02-shCont and SB225002-treated Panc02-shCont tumors. Bar: 50 μm. (G) The number of MPO⁺ cells per field (×400 magnification) in Panc02-shCont (n = 22 fields of 4 tissue sections) and Panc02-sh#5 tumors (n = 17 fields of 5 tissue sections). (H) Angiogenesis. CD31 staining. Bar: 100 μm. (I) Tumor vessel density in Panc02-shCont and SB225002-treated Panc02-shCont tumors (n = 20 fields of 6–8 tissue sections). The data are shown as the mean ± SD. *P<0.05. **P<0.01.

Discussion

We described that sST2 downregulation in Panc02 cells resulted in suppression of tumor growth in the pancreas. This effect was dependent on host-derived IL-33 because Panc02 cells do not secrete IL-33, and we did not detect the suppressive effect in IL-33 knockout mice. Although IL-33 has been shown to induce apoptosis in MIAPaCa-2 cells [26], we did not detect cell death in rIL-33-treated Panc02-shCont cells. Therefore, it seemed likely that the decrease in sST2 in the tumor microenvironment led to activation of IL-33/ST2L signaling, leading to either activation or suppression of other genes in stromal cells. One such gene seemed to be Cxcl3, which was identified by analysis of the expression of cytokines and chemokines; that is, Cxcl3 expression was suppressed in sST2-downregulated orthotopic tumor tissues. CXCL3 has been shown to bind to the receptor CXCR2 and thereby activate migration of neutrophils and endothelial cells [34–38]. Accordingly, immunostaining of the tumor tissues for MPO showed a decrease in the number of MPO⁺ cells in Panc02-sh#5 tumors compared with that of Panc02-shCont tumors. The decrease in neutrophil infiltration was also supported by reduced expression of the neutrophil marker gene Ly6G in Panc02-sh#5 tumors. Although the role of neutrophils in cancer is still controversial, the presence of high numbers of tumor-associated neutrophils (TANs) has been reported to be associated with worse outcomes in several solid tumors [38–42]. Therefore, the decrease in neutrophils in Panc02-sh#5 tumors may be associated with the slow orthotopic growth of the tumors. Furthermore, CD31 staining revealed a decrease in tumor vessel density, which may also be responsible for the slow orthotopic growth. These results were corroborated by SB225002 administration experiments in which SB225002 slowed orthotopic tumor growth of Panc02-shCont cells, accompanied by decreases in neutrophil infiltration and vessel density. It should be noted that the number of TANs in Panc02-sh#5 tumors was not different from that in Panc02-shCont tumors, which quite contrasted with the results obtained in colon cancers [22].

It remains to be determined how sST2 downregulation leads to a decrease in Cxcl3 expression. A previous study showed that IL-33 slightly downregulates Cxcl3 expression in human alveolar type-II-like A549 cells [43]. We observed here that rIL-33 only slightly enhanced Cxcl3 expression in Panc02 cells. Based on these results, it is plausible that IL-33 secreted from stellate cells or CAFs acts on other cells, such as macrophages, that are reported to express ST2L and CXCL3 [7–9, 44], rather than on tumor cells themselves to stimulate the secretion of CXCL3. It is possible that a decrease in sST2 in the orthotopic tumor microenvironment activates IL-33/ST2L signaling in stellate cell-TAM or CAF-TAM interactions, which results in the suppression of Cxcl3 expression. Further studies are necessary to evaluate this possibility.

We found that CXCL5 was abundantly expressed in orthotopic tumors. CXCL1, CXCL2, CXCL3 and CXCL5 all bind to CXCR2 [45]. Thus, one can argue that CXCL3 downregulation is of no importance in the presence of a large amount of CXCL5. With regard to this point, it is noteworthy that CXCL5 is reported to bind to the Duffy antigen receptor for chemokines (DARC) that is expressed in endothelial cells and erythrocytes and acts as a decoy chemokine receptor [45, 46]. DARC has a higher affinity for CXCL5 than other neutrophil chemokines, such as CXCL1 and CXCL2, and therefore, when all of these chemokines are present, CXCL5 remains bound to DARC, leaving CXCL1 and CXCL2 free and active [46]. If such is the case with CXCL3, it could act as the main chemokine to recruit neutrophils and stimulate angiogenesis in the tumors because CXCL3 is more abundant than CXCL1 and CXCL2. Further studies are needed to examine this issue.

On the other hand, a marked increase in the expression of the B cell chemoattractant Cxcl13 in Panc02-sh#5 tumors was evident when examined by a PCR array. However, RT-qPCR analysis showed that the expression varied significantly from tumor tissue to tumor tissue; therefore, no statistically significant difference was obtained between Panc02-shCont and Panc02-sh#5 tumors. Accordingly, we did not observe a significant difference in the number of tumor-infiltrating B cells between the Panc02-sh#5 and Panc02-shCont tumors. We hypothesized that this variation might be due to the region of the tumor tissues from which the RNA was isolated, in which B cells could show skewed distribution.

We previously reported that sST2-knockdown mouse colon cancer cells are less malignant than control cells [22, 47]. Therefore, the present findings are unexpected. However, recent reports have demonstrated that the pancreatic but not subcutaneous tumor microenvironment preferentially confers highly malignant properties to pancreatic cancer cells [48], and gene expression profiles in pancreatic cancer are different between orthotopic and subcutaneous conditions [49]. These data indicate that the microenvironment in the pancreas is composed of a variety of components, including pancreatic stellate cells, endothelial cells, immune cells and endocrine cells, and is very different from that in other organs, and it may profoundly affect the malignant properties of sST2-expressing pancreatic cancer cells. However, the limitation of this study is that we utilized an orthotopic implantation model, which could be a potential source of bias in interpreting the results. In addition, because there are few murine pancreatic cancer cell lines that are well characterized and can be investigated from an immunological point of view in syngeneic mice, the present findings remain generalizable to other pancreatic cancer cell lines in general. Further studies using a spontaneous pancreatic cancer mouse model in which the Il33 or ST2 (IL1RL1) gene is genetically engineered are required in the future.

Conclusions

In the public prognosis databases, we could not find a consistent association between ST2 expression and the prognosis of pancreatic cancer patients. We hypothesized that this may be attributed to a lack of consideration of the effect of sST2 on pancreatic cancer growth. In fact, the present study demonstrated that activation of the IL-33/ST2L axis by suppressing sST2 in the tumor microenvironment inhibited orthotopic tumor growth of Panc02 cells. These results suggest that targeting sST2 in the tumor microenvironment might inhibit tumor growth of sST2-expressing human pancreatic cancers, which is worth exploring in the future. Our results also indicate the CXCL3-CXCR2 axis as a therapeutic target.

Supporting information

S1 Table. Primers used for qRT-PCR.

(TIF)

Click here for additional data file.^{(679.9KB, tif)}

S1 Fig. Correlation of IL-33 and ST2 (IL1RL1) gene expression in cancer tissues and overall survival of pancreatic cancer patients.

(TIF)

Click here for additional data file.^{(190.7KB, tif)}

S2 Fig. qRT-PCR analysis of the expression of ST2L and sST2.

The expression level is expressed as ΔCt. (A) Human pancreatic cancer cell lines. (B) Mouse pancreatic cancer Panc02 cells. moST2L: mouse ST2L; mosST2: mouse sST2. ND: not detected.

(TIF)

Click here for additional data file.^{(99.8KB, tif)}

S3 Fig. Expression and secretion of IL-33 in Panc02 parent and variant cells.

Expression and secretion of IL-33 in Panc02 parent and variant cells. (A) qRT-PCR analysis of the expression of IL-33 mRNA in Panc02 cells and mouse colon carcinoma NM11 cells (Nat Commun. 2016;7:13589) (left panel) in which IL-33 is localized in the nucleus (right panel). (B) Secretion of IL-33. Cells (4 × 10⁴ cells/100 μl) were cultured for 24 h, and the conditioned media were subjected to IL-33 ELISA analysis. The amount of IL-33 was below the detection limits.

(TIF)

Click here for additional data file.^{(195.1KB, tif)}

S4 Fig. Effect of rIL-33 on the survival of Panc02 cells.

The cells were treated with the indicated concentrations of rIL-33 for 48 h. An MTT assay was used to measure cell survival.

(TIF)

Click here for additional data file.^{(124KB, tif)}

S5 Fig. Serum sST2 and IL-33 levels in mice bearing Panc02-shCont, Panc02-sh#3 and Panc02-sh#5 tumors.

(A) sST2. (B) IL-33. Sera of the mice bearing shCont tumors (n = 5), sh#3 tumors (n = 4) and sh#5 tumors (n = 4) were used. *P<0.001 compared to shCont.

(TIF)

Click here for additional data file.^{(83.5KB, tif)}

S6 Fig. IL-33 immunohistochemistry.

Sections of Panc02-shCont orthotopic tumors were immunostained for IL-33 and α-SMA. Bar: 50 μm.

(TIF)

Click here for additional data file.^{(898.2KB, tif)}

S7 Fig. Ramaswamy dataset of Cxcl3 expression in various human tumors (Oncomine).

(TIF)

Click here for additional data file.^{(314KB, tif)}

S8 Fig. qRT-PCR analyses of the effect of rIL-33 on the expression of sST2 and ST2L in Panc02 cells.

(A) The cells were treated with the indicated concentrations of rIL-33 for 6 h. (B) The cells were treated with 50 ng/ml rIL-33 for the indicated times. *P<0.05 compared to untreated cells.

(TIF)

Click here for additional data file.^{(149.3KB, tif)}

S9 Fig. qRT-PCR analyses of the effect of rIL-33 on the expression of Cxcl3 in Panc02 cells.

(A) The cells were treated with the indicated concentrations of rIL-33 for 6 h. (B) The cells were treated with 50 ng/ml rIL-33 for the indicated times.

(TIF)

Click here for additional data file.^{(81.2KB, tif)}

Acknowledgments

Some animal experiments were performed in the animal center of Shimane University Faculty of Medicine.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported in part by JSPS KAKENHI (https://www.jsps.go.jp/) Grant Number 25430110 and by JSPS KAKENHI Grant Number 24791422 to M.A. The funding bodies had no role in the design of the study and data collection, analysis, and interpretation of data and in preparing the manuscript.

References

1.Loc WS, Smith JP, Matters G, Kester M, Adair JH. Novel strategies for managing pancreatic cancer. World J. Gastroenterol. 2014; 20: 14717–14725. 10.3748/wjg.v20.i40.14717 [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Partensky C. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope? Pancreas. 2013; 42: 729–739. 10.1097/MPA.0b013e318288107a [DOI] [PubMed] [Google Scholar]
3.Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev. Gastroenterol. Hepatol. 2016; 10: 301–316. 10.1586/17474124.2016.1117386 [DOI] [PubMed] [Google Scholar]
4.Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat. Rev. Clin. Oncol. 2013; 10, 323–333. 10.1038/nrclinonc.2013.66 [DOI] [PubMed] [Google Scholar]
5.Ben-Josef E, Lawrence TS. Radiotherapy: the importance of local control in pancreatic cancer. Nat. Rev. Clin. Oncol. 2012; 9: 9–10. 10.1038/nrclinonc.2011.182 [DOI] [PubMed] [Google Scholar]
6.Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989; 258: 301–304. 10.1016/0014-5793(89)81679-5 [DOI] [PubMed] [Google Scholar]
7.Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem. Biophys. Res. Commun. 2001; 285: 1377–1383. 10.1006/bbrc.2001.5306 [DOI] [PubMed] [Google Scholar]
8.Liew FY. IL-33: a Janus cytokine. Ann. Rheum. Dis. 2012; 71: i101–i104. 10.1136/annrheumdis-2011-200589 [DOI] [PubMed] [Google Scholar]
9.Trajkovic V, Sweet MJ, Xu D. T1/ST2—an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 2004; 15: 87–95. 10.1016/j.cytogfr.2004.02.004 [DOI] [PubMed] [Google Scholar]
10.Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994; 13: 1176–1188. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin. Exp. Allergy. 2002; 32: 1520–1526. 10.1046/j.1365-2745.2002.01494.x [DOI] [PubMed] [Google Scholar]
12.Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One. 2008; 3: e3331 10.1371/journal.pone.0003331 e3331. [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem. Biophys. Res. Commun. 2009; 384: 105–109. 10.1016/j.bbrc.2009.04.081 [DOI] [PubMed] [Google Scholar]
14.Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol. Int. 2010; 59: 143–160. 10.2332/allergolint.10-RAI-0186 [DOI] [PubMed] [Google Scholar]
15.Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010; 10: 103–110. 10.1038/nri2692 [DOI] [PubMed] [Google Scholar]
16.Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23: 479–490. 10.1016/j.immuni.2005.09.015 [DOI] [PubMed] [Google Scholar]
17.Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig. Dis. Sci. 2011; 56: 3596–3601. 10.1007/s10620-011-1760-5 [DOI] [PubMed] [Google Scholar]
18.Hu L-A, Fu Y, Zhang D-N, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac. J. Cancer Prev. 2013; 14: 2563–2566. 10.7314/apjcp.2013.14.4.2563 [DOI] [PubMed] [Google Scholar]
19.Zhang P, Liu XK, Chu Z, Ye JC, Li KL, Zhuang WL, et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J. Int. Med. Res. 2012; 40: 1654–1661. 10.1177/030006051204000504 [DOI] [PubMed] [Google Scholar]
20.Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer. 2014; 134: 1669–1682. 10.1002/ijc.28481 [DOI] [PubMed] [Google Scholar]
21.Janakira NB, Rao CV. The role of inflammation in colon cancer. Adv. Exp. Med. Biol. 2014; 816: 25–52. 10.1007/978-3-0348-0837-8_2 [DOI] [PubMed] [Google Scholar]
22.Akimoto M, Maruyama R, Takamaru H, Ochiya T, Takenaga K. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumor microenvironment. Nat. Commun. 2016; 7: 13589 10.1038/ncomms13589 [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Gao K, Li X, Zhang L, Bai L, Dong W, Gao K, et al. Transgenic expression of IL-33 activates CD8⁺ T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 2013; 335: 463–471. 10.1016/j.canlet.2013.03.002 [DOI] [PubMed] [Google Scholar]
24.Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8⁺ T and NK cells. J. Immunol. 2015; 194: 438–445. 10.4049/jimmunol.1401344 [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. 2012; 60: 514–521. 10.1016/j.cyto.2012.06.286 [DOI] [PubMed] [Google Scholar]
26.Fang Y, Zhao L, Xiao H, Cook KM, Bai Q, Herrick EJ, et al. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Med. Oncol. 2017; 34: 23 10.1007/s12032-016-0880-3 [DOI] [PubMed] [Google Scholar]
27.Akimoto M, Iizuka M, Kanematsu R, Yoshida M, Takenaga K. Anticancer effect of ginger extract against pancreatic cancer cells mainly through reactive oxygen species-mediated autotic cell death. PLoS One. 2015; 10: e0126605 10.1371/journal.pone.0126605 [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44: 717–726. [PubMed] [Google Scholar]
29.Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA. 2010; 107: 18581–18586. 10.1073/pnas.1003059107 [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Steinmetz OM, Stahl RA, Panzer U. Chemokines and B cells in renal inflammation and allograft rejection. Front. Biosci (Schol Ed). 2009; 1: 13–22. [DOI] [PubMed] [Google Scholar]
31.Smith DF, Galkina E, Ley K, Huo Y. GRO family chemokines are specialized for monocyte arrest from flow. Am. J. Physiol. Heart Circ. Physiol. 2005; 289: H1976–H1984. 10.1152/ajpheart.00153.2005 [DOI] [PubMed] [Google Scholar]
32.Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 1996; 271: 20545–20550. 10.1074/jbc.271.34.20545 [DOI] [PubMed] [Google Scholar]
33.Reich N, Beyer C, Gelse K, Akhmetshina A, Dees C, Zwerina J, et al. Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. J. Cell Mol. Med. 2011; 15: 756–762. 10.1111/j.1582-4934.2010.01051.x [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Vandercappellen J, Van DJ, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267: 226–244. 10.1016/j.canlet.2008.04.050 [DOI] [PubMed] [Google Scholar]
35.Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 1995; 270: 27348–27357. 10.1074/jbc.270.45.27348 [DOI] [PubMed] [Google Scholar]
36.Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR ⁺ CXC chemokine-induced angiogenic activity. J. Immunol. 2000; 165: 5269–5277. 10.4049/jimmunol.165.9.5269 [DOI] [PubMed] [Google Scholar]
37.Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J. Immunol. 2005; 175: 5351–5357. 10.4049/jimmunol.175.8.5351 [DOI] [PubMed] [Google Scholar]
38.Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol. Cancer. 2017; 16: 137 10.1186/s12943-017-0707-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2014; 106: dju124 10.1093/jnci/dju124 [DOI] [PubMed] [Google Scholar]
40.Selders GS, Fetz AE, Radic MZ, Bowlin GL. An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. Regen. Biomater. 2017; 4: 55–68. 10.1093/rb/rbw041 [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, et al. Change in Neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur. Urol. 2016; 70: 358–364. 10.1016/j.eururo.2016.02.033 [DOI] [PubMed] [Google Scholar]
42.Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 2009; 27: 4709–4717. 10.1200/JCO.2008.18.9498 [DOI] [PubMed] [Google Scholar]
43.Brabcová E, Kolesár L, Thorburn E, Stříž I. Chemokines induced in human respiratory epithelial cells by IL-1 family of cytokines. Folia Biol (Praha). 2014; 60: 180–186. [DOI] [PubMed] [Google Scholar]
44.Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, Braun H Liu S, et al. Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis. JCI Insight. 2018. October 18;3(20). pii: 122375 10.1172/jci.insight.122375 [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Bonecchi R, Savino B, Borroni EM, Mantovani A, Locati M. Chemokine decoy receptors: structure-function and biological properties. Curr. Top. Microbiol Immunol. 2010; 341: 15–36. 10.1007/82_2010_19 [DOI] [PubMed] [Google Scholar]
46.Koltsova EK, Ley K. The mysterious ways of the chemokine CXCL5. Immunity. 2010; 33: 7–9. 10.1016/j.immuni.2010.07.012 [DOI] [PubMed] [Google Scholar]
47.Akimoto M, Takenaga K. Role of the IL-33/ST2L axis in colorectal cancer progression. Cell. Immunol. 2018; pii:S0008-8749(17)30241-1. 10.1016/j.cellimm.2017.12.014 [DOI] [PubMed] [Google Scholar]
48.Takahashi K, Ehata S, Koinuma D, Morishita Y, Soda M, Mano H, et al. Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells. Oncogene. 2018; 37: 2757–2772. 10.1038/s41388-018-0144-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Hoover M, Adamian Y, Brown M, Maawy A, Chang A, Lee J, et al. A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts. Oncotarget. 2017; 8: 5885–5894. 10.18632/oncotarget.11809 [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0232230.r001

Decision Letter 0

Sulagna Banerjee

27 Feb 2020

PONE-D-19-33979

Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model

PLOS ONE

Dear Takenaga,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Apr 12 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Sulagna Banerjee

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf and http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript
A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)
A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. Please provide additional information about each of the cell lines used in this work, including any quality control testing procedures (authentication, characterisation, and mycoplasma testing). For more information, please see http://journals.plos.org/plosone/s/submission-guidelines#loc-cell-lines.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: IL-33 has been widely studied in inflammatory diseases, but its role in cancer is somewhat paradoxical. Human pancreatic cancer is one of the deadliest malignancies wherein the inflammation of the pancreas plays a critical role. This research paper entitled “Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model” encompasses some interesting findings wherein following issues should be addressed.

Minor Concerns:

1. Fig. 1 legend can be made more explanatory.

2. Fig. 4 legend need correction wherein last line saying *p<0.005 should be corrected as *p<0.05.

Major Concerns:

1. Fig.1: Authors should provide a plot for Δct values for ST2l and sST2 for all human and mouse cell lines in either Fig 1 or supplementary.

2. Fig 2: It would have been a better comparison to see the effect of knocking down the sST2 and ST2l individually instead of employing sh#3 shRNA which collectively knocks down both ST2l and sST2. Have authors used any shRNA to knock down ST2l individually? If so, please include the data to draw a better comparison and so the effect on tumor volume and tumor weight.

3. In Fig 3E and F the tumor volume and weight is approximately half fold in samples where sST2 is rescued as compared to control. Please discuss.

4. Fig 4A shows expression of IL-33 mRNA by RT-PCR. Since sST2 act as IL-33 sink, authors should show the expression of secretory IL-33 which is expected to up-regulate in sh#5 as compared to shCont.

Since idea of the paper is, Cancer cell-derived sST2 enhances tumor growth through upregulation of CXCL3 via inhibition of IL-33-ST2L signaling in the tumor microenvironment of pancreatic cancer, the expression of secretory IL-33 in sh#5 and shCont would be an essential piece of data to corroborate the finding in IL-33 knock out mice wherein decoy receptor seems to has no effect. Please include the said figure in Fig 4.

Reviewer #2: Here, Takenaga and colleagues conducted an in vivo study to explore the role of cancer cell derived IL-33 decoy receptor sST2 in pancreatic tumor growth. This is an interesting study as this one relatively new in pancreatic cancer and almost unexplored. The author precisely investigated the involvement of decoy receptor in tumor progression. However, in my opinion the manuscript has some shortcomings. Below I have provided numerous remarks. Please address the following concern.

Comments:

1. What is the source of IL-33 in TME. Is it pancreatic stellate cell or other cell types?

2. As a ligand, is IL-33 regulate the secretion of receptor sST2 from pancreatic cancer cell? If so, which control the secretion of receptor sST2 in global IL-33 KO mice. It is interesting to see that IL-33 signaling downregulate CXCL-3 expression, what could be the possible mechanism?

3. In figure3 panel E and F, is VC and sST2 are statistically significant?

4. It will be worthy, in future to perform some coculture experiment with PANC02 cell and CAF cell to better understand their cytokine/chemokine crosstalk in TME.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Utpreksha Vaish

Reviewer #2: Yes: kousik kumar kesh

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: plos one review.docx

Click here for additional data file.^{(12.5KB, docx)}

PLoS One. 2020 Apr 27;15(4):e0232230. doi: 10.1371/journal.pone.0232230.r002

Author response to Decision Letter 0

27 Mar 2020

Response to reviewers

Journal requirements

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Reply: We have ensured that our manuscript meets the style requirements of PLOS ONE.

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar.

Reply: Our manuscript has been thoroughly edited by SPRINGER NATURE Author Services. We have attached the certificate.

3. Please provide additional information about each of the cell lines used in this work, including any quality control testing procedures (authentication, characterisation, and mycoplasma testing).

Reply: We have provided additional information about Panc02 cells and mycoplasma testing (page 6, lines 106-108 and 113-115).

Reviewer #1

Major comments:

1. Fig. 1 legend can be made more explanatory.

Reply: Thank you for the comment. We have changed the legend.

2. Fig. 4 legend need correction wherein last line saying *p<0.005 should be corrected as *p<0.05.

Reply: We have corrected the p value.

Minor comments:

1. Fig.1: Authors should provide a plot for Δct values for ST2l and sST2 for all human and mouse cell lines in either Fig 1 or supplementary.

Reply: We have provided a plot showing the ΔCt values in the Supporting information (S1 Fig).

Reply: Unfortunately, shRNAs that specifically knock down only ST2L were not available at the time we started the experiments. Therefore, we did not compare the effect of individual knock down of ST2L and sST2.

3. In Fig 3E and F the tumor volume and weight is approximately half fold in samples where sST2 is rescued as compared to control. Please discuss.

Reply: As the reviewer pointed out, the growth of sh#5-sST2 tumors was not recovered to the level of shCont tumors. We do not know the reason, but it could be due to insufficient recovery of sST2 or off-target effects of the introduced expression by the plasmid and the G418 selection procedure of the introduced cells. We have discussed this point in the text (page 16, lines 323-325).

4. Fig 4A shows expression of IL-33 mRNA by RT-PCR. Since sST2 act as IL-33 sink, authors should show the expression of secretory IL-33 which is expected to up-regulate in sh#5 as compared to shCont. Since idea of the paper is, Cancer cell-derived sST2 enhances tumor growth through upregulation of CXCL3 via inhibition of IL-33-ST2L signaling in the tumor microenvironment of pancreatic cancer, the expression of secretory IL-33 in sh#5 and shCont would be an essential piece of data to corroborate the finding in IL-33 knock out mice wherein decoy receptor seems to has no effect. Please include the said figure in Fig 4.

Reply: We appreciate the comment very much. In separate experiments, we measured the levels of IL-33 and sST2 in the sera of mice bearing shCont, sh#3 and sh#5 tumors, as shown in Supporting information (S5 Fig). The results showed that serum sST2 levels were considerably decreased in the mice bearing sh#3 and sh#5 tumors compared to those bearing shCont tumors, whereas the levels of IL-33 were comparable among them. As the reviewer suggested, sST2 acts as an IL-33 sink, and thus, we expected that the IL-33 level would be increased in the sera of mice bearing sh#3 and sh#5 tumors. However, this was not the case. We hypothesize that this may be because the anti-IL-33 antibody used in the ELISA cannot differentiate free IL-33 from sST2-bound IL-33. Based on these observations, the comparison of IL-33 protein by ELISA between sh#5 tumors and shCont tumors does not provide concrete evidence indicating the role of sST2 as an IL-33 sink.

Reviewer #2

1. What is the source of IL-33 in TME. Is it pancreatic stellate cell or other cell types?

Reply: We appreciate the comment very much. We investigated the source of IL-33 in the TME by immunohistochemistry and found that α-smooth muscle actin+ cells were positive for IL-33. These cells could be pancreatic stellate cells or cancer-associated fibroblasts. The results are provided in the Supplementary information (S6 Fig).

Reply: We investigated the effects of rIL-33 on the expression of sST2 and ST2L in Panc02 cells and found that rIL-33 significantly increased the expression of both sST2 and ST2L (see Supplementary information S8 Fig). Because Panc02 cells do not secrete IL-33 (see Supplementary information S3 Fig), these results indicate that host-derived IL-33 partially regulates the expression of sST2 via IL-33-ST2L signaling. It has been shown that sST2 expression is regulated by oncogenes, serum and other mitogenic stimuli (Eur. J. Immunol. 2012. 42: 1863–1869). Therefore, in IL-33 KO mice, sST2 seems to be induced in response to these stimuli.

We also investigated the effect of rIL-33 on CXCL-3 expression in Panc02 cells. We found that Panc02 cells expressed little CXCL-3, and rIL-33 only slightly enhanced the expression (see Supplementary information S9 Fig). However, the increase seemed to be marginal. Therefore, IL-33 may act on stromal cells rather than tumor cells to enhance CXCL-3 secretion in the tumor microenvironment.

3. In figure 3 panel E and F, is VC and sST2 are statistically significant?

Reply: Thank you for the comment. Yes, the difference between VC and sST2 was statistically significant. We have included the p-value in Figure 3 panels E and F.

4. It will be worthy, in future to perform some coculture experiment with PANC02 cell and CAF cell to better understand their cytokine/chemokine crosstalk in TME.

Reply: We appreciate the comment. We want to perform experiments in the future.

Attachment

Submitted filename: Response to reviewers.docx

Click here for additional data file.^{(18.5KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0232230.r003

Decision Letter 1

Sulagna Banerjee

10 Apr 2020

Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model

PONE-D-19-33979R1

Dear Dr. Takenaga,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Sulagna Banerjee

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Reviewer #1: Author' reply for Δct plots for ST2 and sST2-We have provided a plot showing the ΔCt values in the Supporting information (S1 Fig).

Reviewer's comment- This is actually S2 Fig. Check it throughput the manuscript and make correction if any required.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Utpreksha Vaish

Reviewer #2: Yes: kousik kumar kesh

PLoS One. doi: 10.1371/journal.pone.0232230.r004

Acceptance letter

Sulagna Banerjee

16 Apr 2020

PONE-D-19-33979R1

Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model

Dear Dr. Takenaga:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sulagna Banerjee

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Table. Primers used for qRT-PCR.

(TIF)

Click here for additional data file.^{(679.9KB, tif)}

S1 Fig. Correlation of IL-33 and ST2 (IL1RL1) gene expression in cancer tissues and overall survival of pancreatic cancer patients.

(TIF)

Click here for additional data file.^{(190.7KB, tif)}

S2 Fig. qRT-PCR analysis of the expression of ST2L and sST2.

The expression level is expressed as ΔCt. (A) Human pancreatic cancer cell lines. (B) Mouse pancreatic cancer Panc02 cells. moST2L: mouse ST2L; mosST2: mouse sST2. ND: not detected.

(TIF)

Click here for additional data file.^{(99.8KB, tif)}

S3 Fig. Expression and secretion of IL-33 in Panc02 parent and variant cells.

(TIF)

Click here for additional data file.^{(195.1KB, tif)}

S4 Fig. Effect of rIL-33 on the survival of Panc02 cells.

The cells were treated with the indicated concentrations of rIL-33 for 48 h. An MTT assay was used to measure cell survival.

(TIF)

Click here for additional data file.^{(124KB, tif)}

S5 Fig. Serum sST2 and IL-33 levels in mice bearing Panc02-shCont, Panc02-sh#3 and Panc02-sh#5 tumors.

(A) sST2. (B) IL-33. Sera of the mice bearing shCont tumors (n = 5), sh#3 tumors (n = 4) and sh#5 tumors (n = 4) were used. *P<0.001 compared to shCont.

(TIF)

Click here for additional data file.^{(83.5KB, tif)}

S6 Fig. IL-33 immunohistochemistry.

Sections of Panc02-shCont orthotopic tumors were immunostained for IL-33 and α-SMA. Bar: 50 μm.

(TIF)

Click here for additional data file.^{(898.2KB, tif)}

S7 Fig. Ramaswamy dataset of Cxcl3 expression in various human tumors (Oncomine).

(TIF)

Click here for additional data file.^{(314KB, tif)}

S8 Fig. qRT-PCR analyses of the effect of rIL-33 on the expression of sST2 and ST2L in Panc02 cells.

(A) The cells were treated with the indicated concentrations of rIL-33 for 6 h. (B) The cells were treated with 50 ng/ml rIL-33 for the indicated times. *P<0.05 compared to untreated cells.

(TIF)

Click here for additional data file.^{(149.3KB, tif)}

S9 Fig. qRT-PCR analyses of the effect of rIL-33 on the expression of Cxcl3 in Panc02 cells.

(A) The cells were treated with the indicated concentrations of rIL-33 for 6 h. (B) The cells were treated with 50 ng/ml rIL-33 for the indicated times.

(TIF)

Click here for additional data file.^{(81.2KB, tif)}

Attachment

Submitted filename: plos one review.docx

Click here for additional data file.^{(12.5KB, docx)}

Attachment

Submitted filename: Response to reviewers.docx

Click here for additional data file.^{(18.5KB, docx)}

Data Availability Statement

All relevant data are within the manuscript and its Supporting Information files.

[pone.0232230.ref001] 1.Loc WS, Smith JP, Matters G, Kester M, Adair JH. Novel strategies for managing pancreatic cancer. World J. Gastroenterol. 2014; 20: 14717–14725. 10.3748/wjg.v20.i40.14717 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref002] 2.Partensky C. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope? Pancreas. 2013; 42: 729–739. 10.1097/MPA.0b013e318288107a [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref003] 3.Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev. Gastroenterol. Hepatol. 2016; 10: 301–316. 10.1586/17474124.2016.1117386 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref004] 4.Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat. Rev. Clin. Oncol. 2013; 10, 323–333. 10.1038/nrclinonc.2013.66 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref005] 5.Ben-Josef E, Lawrence TS. Radiotherapy: the importance of local control in pancreatic cancer. Nat. Rev. Clin. Oncol. 2012; 9: 9–10. 10.1038/nrclinonc.2011.182 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref006] 6.Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989; 258: 301–304. 10.1016/0014-5793(89)81679-5 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref007] 7.Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem. Biophys. Res. Commun. 2001; 285: 1377–1383. 10.1006/bbrc.2001.5306 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref008] 8.Liew FY. IL-33: a Janus cytokine. Ann. Rheum. Dis. 2012; 71: i101–i104. 10.1136/annrheumdis-2011-200589 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref009] 9.Trajkovic V, Sweet MJ, Xu D. T1/ST2—an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 2004; 15: 87–95. 10.1016/j.cytogfr.2004.02.004 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref010] 10.Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994; 13: 1176–1188. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref011] 11.Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin. Exp. Allergy. 2002; 32: 1520–1526. 10.1046/j.1365-2745.2002.01494.x [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref012] 12.Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One. 2008; 3: e3331 10.1371/journal.pone.0003331 e3331. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref013] 13.Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem. Biophys. Res. Commun. 2009; 384: 105–109. 10.1016/j.bbrc.2009.04.081 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref014] 14.Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol. Int. 2010; 59: 143–160. 10.2332/allergolint.10-RAI-0186 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref015] 15.Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010; 10: 103–110. 10.1038/nri2692 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref016] 16.Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23: 479–490. 10.1016/j.immuni.2005.09.015 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref017] 17.Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig. Dis. Sci. 2011; 56: 3596–3601. 10.1007/s10620-011-1760-5 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref018] 18.Hu L-A, Fu Y, Zhang D-N, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac. J. Cancer Prev. 2013; 14: 2563–2566. 10.7314/apjcp.2013.14.4.2563 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref019] 19.Zhang P, Liu XK, Chu Z, Ye JC, Li KL, Zhuang WL, et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J. Int. Med. Res. 2012; 40: 1654–1661. 10.1177/030006051204000504 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref020] 20.Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer. 2014; 134: 1669–1682. 10.1002/ijc.28481 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref021] 21.Janakira NB, Rao CV. The role of inflammation in colon cancer. Adv. Exp. Med. Biol. 2014; 816: 25–52. 10.1007/978-3-0348-0837-8_2 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref022] 22.Akimoto M, Maruyama R, Takamaru H, Ochiya T, Takenaga K. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumor microenvironment. Nat. Commun. 2016; 7: 13589 10.1038/ncomms13589 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref023] 23.Gao K, Li X, Zhang L, Bai L, Dong W, Gao K, et al. Transgenic expression of IL-33 activates CD8⁺ T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 2013; 335: 463–471. 10.1016/j.canlet.2013.03.002 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref024] 24.Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8⁺ T and NK cells. J. Immunol. 2015; 194: 438–445. 10.4049/jimmunol.1401344 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref025] 25.Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. 2012; 60: 514–521. 10.1016/j.cyto.2012.06.286 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref026] 26.Fang Y, Zhao L, Xiao H, Cook KM, Bai Q, Herrick EJ, et al. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Med. Oncol. 2017; 34: 23 10.1007/s12032-016-0880-3 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref027] 27.Akimoto M, Iizuka M, Kanematsu R, Yoshida M, Takenaga K. Anticancer effect of ginger extract against pancreatic cancer cells mainly through reactive oxygen species-mediated autotic cell death. PLoS One. 2015; 10: e0126605 10.1371/journal.pone.0126605 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref028] 28.Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44: 717–726. [PubMed] [Google Scholar]

[pone.0232230.ref029] 29.Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA. 2010; 107: 18581–18586. 10.1073/pnas.1003059107 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref030] 30.Steinmetz OM, Stahl RA, Panzer U. Chemokines and B cells in renal inflammation and allograft rejection. Front. Biosci (Schol Ed). 2009; 1: 13–22. [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref031] 31.Smith DF, Galkina E, Ley K, Huo Y. GRO family chemokines are specialized for monocyte arrest from flow. Am. J. Physiol. Heart Circ. Physiol. 2005; 289: H1976–H1984. 10.1152/ajpheart.00153.2005 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref032] 32.Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 1996; 271: 20545–20550. 10.1074/jbc.271.34.20545 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref033] 33.Reich N, Beyer C, Gelse K, Akhmetshina A, Dees C, Zwerina J, et al. Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. J. Cell Mol. Med. 2011; 15: 756–762. 10.1111/j.1582-4934.2010.01051.x [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref034] 34.Vandercappellen J, Van DJ, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267: 226–244. 10.1016/j.canlet.2008.04.050 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref035] 35.Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 1995; 270: 27348–27357. 10.1074/jbc.270.45.27348 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref036] 36.Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR ⁺ CXC chemokine-induced angiogenic activity. J. Immunol. 2000; 165: 5269–5277. 10.4049/jimmunol.165.9.5269 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref037] 37.Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J. Immunol. 2005; 175: 5351–5357. 10.4049/jimmunol.175.8.5351 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref038] 38.Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol. Cancer. 2017; 16: 137 10.1186/s12943-017-0707-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref039] 39.Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2014; 106: dju124 10.1093/jnci/dju124 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref040] 40.Selders GS, Fetz AE, Radic MZ, Bowlin GL. An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. Regen. Biomater. 2017; 4: 55–68. 10.1093/rb/rbw041 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref041] 41.Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, et al. Change in Neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur. Urol. 2016; 70: 358–364. 10.1016/j.eururo.2016.02.033 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref042] 42.Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 2009; 27: 4709–4717. 10.1200/JCO.2008.18.9498 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref043] 43.Brabcová E, Kolesár L, Thorburn E, Stříž I. Chemokines induced in human respiratory epithelial cells by IL-1 family of cytokines. Folia Biol (Praha). 2014; 60: 180–186. [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref044] 44.Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, Braun H Liu S, et al. Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis. JCI Insight. 2018. October 18;3(20). pii: 122375 10.1172/jci.insight.122375 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref045] 45.Bonecchi R, Savino B, Borroni EM, Mantovani A, Locati M. Chemokine decoy receptors: structure-function and biological properties. Curr. Top. Microbiol Immunol. 2010; 341: 15–36. 10.1007/82_2010_19 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref046] 46.Koltsova EK, Ley K. The mysterious ways of the chemokine CXCL5. Immunity. 2010; 33: 7–9. 10.1016/j.immuni.2010.07.012 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref047] 47.Akimoto M, Takenaga K. Role of the IL-33/ST2L axis in colorectal cancer progression. Cell. Immunol. 2018; pii:S0008-8749(17)30241-1. 10.1016/j.cellimm.2017.12.014 [DOI] [PubMed] [Google Scholar]

[pone.0232230.ref048] 48.Takahashi K, Ehata S, Koinuma D, Morishita Y, Soda M, Mano H, et al. Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells. Oncogene. 2018; 37: 2757–2772. 10.1038/s41388-018-0144-0 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0232230.ref049] 49.Hoover M, Adamian Y, Brown M, Maawy A, Chang A, Lee J, et al. A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts. Oncotarget. 2017; 8: 5885–5894. 10.18632/oncotarget.11809 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model

Keizo Takenaga

Miho Akimoto

Nobuko Koshikawa

Hiroki Nagase

Roles

Abstract

Background

Methods

Results

Conclusions

Introduction

Materials and methods

Reagents

Cells and cell culture

ST2 knockdown by shRNAs

Forced sST2 expression in shsST2 knockdown Panc02 cells

MTT assay

RNA preparation and qRT-PCR

Quantification of sST2 and IL-33 by ELISA

Profiling chemokine and cytokine gene expression

Tumor transplantation

SB225002 administration

Immunohistochemical analysis of CD31 using frozen sections

Immunohistochemical analysis of paraffin-embedded tissues

Quantification of CXCL3 in tumor tissues by ELISA

Statistical analysis

Results

Association between IL33 and ST2 expression and prognosis in pancreatic cancer patient databases

Fig 1. Expression of ST2L and sST2 in pancreatic cancer cell lines.

Downregulation of sST2 expression in Panc02 cells inhibits orthotopic tumor growth

Fig 2. sST2 downregulation suppresses orthotopic tumor growth of Panc02 cells.

Fig 3. Suppression of orthotopic tumor growth of Panc02-sh#5 cells is dependent on sST2 and IL-33.

Gene expression of cytokines and chemokines in orthotopic tumors

Fig 4. Expression of IL-33, ST2L, cytokines and chemokines in orthotopic tumors.

CXCL3-mediated infiltration of neutrophils and microvessel density in orthotopic tumors

Fig 5. Infiltration of neutrophils and tumor angiogenesis in orthotopic tumors.

Inhibition of CXCR2 signaling suppresses orthotopic tumor growth

Fig 6. Effect of SB225002 administration on tumor growth, neutrophil infiltration and angiogenesis.

Discussion

Conclusions

Supporting information

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Sulagna Banerjee

Roles

Author response to Decision Letter 0

Decision Letter 1

Sulagna Banerjee

Roles

Acceptance letter

Sulagna Banerjee

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases